Free Trial

Zentalis Pharmaceuticals (ZNTL) Competitors

Zentalis Pharmaceuticals logo
$1.27 +0.08 (+6.72%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$1.30 +0.03 (+2.36%)
As of 08:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZNTL vs. PRTA, TERN, PRME, HUMA, AQST, SNDL, HRTX, AURA, ALT, and CTOR

Should you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Prothena (PRTA), Terns Pharmaceuticals (TERN), Prime Medicine (PRME), Humacyte (HUMA), Aquestive Therapeutics (AQST), SNDL (SNDL), Heron Therapeutics (HRTX), Aura Biosciences (AURA), Altimmune (ALT), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry.

Zentalis Pharmaceuticals vs. Its Competitors

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Prothena has higher revenue and earnings than Zentalis Pharmaceuticals. Prothena is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zentalis Pharmaceuticals$67.43M1.36-$165.84M-$3.13-0.41
Prothena$135.16M2.60-$122.31M-$2.08-3.13

Zentalis Pharmaceuticals presently has a consensus price target of $8.37, indicating a potential upside of 558.79%. Prothena has a consensus price target of $31.50, indicating a potential upside of 383.13%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Zentalis Pharmaceuticals is more favorable than Prothena.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zentalis Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Prothena
1 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Prothena had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 1 mentions for Prothena and 0 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.00 beat Prothena's score of -0.16 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Zentalis Pharmaceuticals Neutral
Prothena Neutral

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Prothena's net margin of -79.94%. Prothena's return on equity of -21.61% beat Zentalis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Zentalis PharmaceuticalsN/A -65.48% -51.05%
Prothena -79.94%-21.61%-19.32%

97.1% of Prothena shares are owned by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are owned by company insiders. Comparatively, 9.2% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Zentalis Pharmaceuticals has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500.

Summary

Prothena beats Zentalis Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Zentalis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZNTL vs. The Competition

MetricZentalis PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$85.62M$2.87B$5.50B$8.95B
Dividend YieldN/A2.45%5.25%4.04%
P/E Ratio-0.4120.8026.9720.11
Price / Sales1.36286.31425.92119.81
Price / CashN/A41.1936.8257.86
Price / Book0.277.487.985.56
Net Income-$165.84M-$55.04M$3.16B$248.40M
7 Day Performance2.42%2.44%2.36%4.67%
1 Month Performance-14.77%1.90%2.15%6.64%
1 Year Performance-69.98%4.35%33.78%21.31%

Zentalis Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZNTL
Zentalis Pharmaceuticals
1.555 of 5 stars
$1.27
+6.7%
$8.37
+558.8%
-69.6%$85.62M$67.43M-0.41160
PRTA
Prothena
3.0445 of 5 stars
$6.07
-0.2%
$31.50
+418.9%
-67.7%$326.75M$135.16M-2.92130
TERN
Terns Pharmaceuticals
3.7045 of 5 stars
$3.73
-2.6%
$15.63
+318.9%
-39.8%$325.78MN/A-3.4240
PRME
Prime Medicine
4.0534 of 5 stars
$2.47
+2.1%
$10.08
+308.2%
-25.3%$324.30M$3.85M-1.20234Options Volume
High Trading Volume
HUMA
Humacyte
2.749 of 5 stars
$2.09
-1.4%
$11.71
+460.5%
-54.7%$324.20M$1.57M-3.03150News Coverage
Gap Up
AQST
Aquestive Therapeutics
1.2446 of 5 stars
$3.31
+1.8%
$10.14
+206.4%
+53.3%$322.82M$54.23M-5.61160
SNDL
SNDL
3.513 of 5 stars
$1.21
-1.6%
$3.63
+199.6%
-29.9%$317.96M$671.81M-4.172,516
HRTX
Heron Therapeutics
3.8245 of 5 stars
$2.07
-3.3%
$5.00
+141.5%
-25.9%$315.80M$144.29M-34.50300Positive News
AURA
Aura Biosciences
1.8841 of 5 stars
$6.26
-0.3%
$22.00
+251.4%
-14.6%$314.69MN/A-3.2950Positive News
ALT
Altimmune
2.22 of 5 stars
$3.87
+10.6%
$19.00
+391.0%
-33.5%$313.90M$20K-3.0750Gap Down
High Trading Volume
CTOR
Citius Oncology
0.3975 of 5 stars
$4.35
-3.3%
$3.00
-31.0%
N/A$311.24MN/A0.00N/A

Related Companies and Tools


This page (NASDAQ:ZNTL) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners